References
- Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-90. https://doi.org/10.1200/JCO.2009.26.2543
- Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:1039-44. https://doi.org/10.1016/j.ijrobp.2007.07.2323
- Ademuyiwa FO, Johnson CS, White AS, et al. Prognostic factors in stage III non-small-cell lung cancer. Clin Lung Cancer 2007;8:478-82. https://doi.org/10.3816/CLC.2007.n.031
- Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 2015;26:1091-101. https://doi.org/10.1093/annonc/mdu540
- Ellis G, Whitehead MA, Robinson D, O'Neill D, Langhorne P. Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials. BMJ 2011;343:d6553. https://doi.org/10.1136/bmj.d6553
- Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103:1452-60. https://doi.org/10.1093/jnci/djr325
- Baumann M, Herrmann T, Koch R, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011;100:76-85. https://doi.org/10.1016/j.radonc.2011.06.031
- Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16:187-99. https://doi.org/10.1016/S1470-2045(14)71207-0
- Vokes EE, Herndon JE 2nd, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698-704. https://doi.org/10.1200/JCO.2006.07.3569
- Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26:5755-60. https://doi.org/10.1200/JCO.2008.17.7840
- Ahn JS, Ahn YC, Kim JH, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSGLU05-04. J Clin Oncol 2015;33:2660-6. https://doi.org/10.1200/JCO.2014.60.0130
- Schild SE, Vokes EE. Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. Ann Oncol 2016;27:590-9. https://doi.org/10.1093/annonc/mdv621
- De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, populationbased study. Ann Oncol 2009;20:98-102.
- Kim YH, Ahn SJ, Kim YC, et al. Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation. Jpn J Clin Oncol 2016;46:144-51.
- Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011;378:1079-88. https://doi.org/10.1016/S0140-6736(11)60780-0
- Takigawa N, Kiura K, Segawa Y, et al. Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007. J Thorac Oncol 2011;6:1087-91. https://doi.org/10.1097/JTO.0b013e318213f86a
- Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014;32:2595-603. https://doi.org/10.1200/JCO.2013.54.8347
- Movsas B, Hu C, Sloan J, et al. Quality of life analysis of a radiation dose-escalation study of patients with non-smallcell lung cancer: a secondary analysis of the Radiation Therapy Oncology Group 0617 randomized clinical trial. JAMA Oncol 2016;2:359-67. https://doi.org/10.1001/jamaoncol.2015.3969
- Ramroth J, Cutter DJ, Darby SC, et al. Dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer: meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 2016;96:736-747. https://doi.org/10.1016/j.ijrobp.2016.07.022
- Yap ML, Sun A, Higgins J, et al. Adaptive dose escalation using serial four-dimensional positron emission tomography/computed tomography scans during radiotherapy for locally advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) 2016;28:e199-e205. https://doi.org/10.1016/j.clon.2016.08.011
- Barriger RB, Fakiris AJ, Hanna N, Yu M, Mantravadi P, McGarry RC. Dose-volume analysis of radiation pneumonitis in nonsmall-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. Int J Radiat Oncol Biol Phys 2010;78:1381-6. https://doi.org/10.1016/j.ijrobp.2009.09.030
- Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S70-6. https://doi.org/10.1016/j.ijrobp.2009.06.091
- Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-smallcell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol 2017;35:56-62.
- Farr KP, Kallehauge JF, Moller DS, et al. Inclusion of functional information from perfusion SPECT improves predictive value of dose-volume parameters in lung toxicity outcome after radiotherapy for non-small cell lung cancer: a prospective study. Radiother Oncol 2015;117:9-16. https://doi.org/10.1016/j.radonc.2015.08.005
- Hodge CW, Tome WA, Fain SB, Bentzen SM, Mehta MP. On the use of hyperpolarized helium MRI for conformal avoidance lung radiotherapy. Med Dosim 2010;35:297-303. https://doi.org/10.1016/j.meddos.2009.09.004
- Vinogradskiy Y, Koo PJ, Castillo R, et al. Comparison of 4-dimensional computed tomography ventilation with nuclear medicine ventilation-perfusion imaging: a clinical validation study. Int J Radiat Oncol Biol Phys 2014;89:199-205. https://doi.org/10.1016/j.ijrobp.2014.01.009
- Speirs CK, Rehman S, Molotievschi A, et al. Comprehensive analysis of dosimetric predictors of overall survival for stage III non-small cell lung cancer (NSCLC) treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys 2014;90(1 Suppl);S667.
- Tucker SL, Liu A, Gomez D, et al. Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiother Oncol 2016;119:495-500. https://doi.org/10.1016/j.radonc.2016.04.025
- Chang JY, Jabbour SK, De Ruysscher D, et al. Consensus statement on proton therapy in early-stage and locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2016;95:505-16. https://doi.org/10.1016/j.ijrobp.2016.01.036
- Nguyen QN, Ly NB, Komaki R, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage IIIII inoperable non-small cell lung cancer. Radiother Oncol 2015;115:367-72. https://doi.org/10.1016/j.radonc.2015.05.014
- Lee H, Ahn YC, Pyo H, et al. Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy. Ann Surg Oncol 2014;21:2083-90. https://doi.org/10.1245/s10434-014-3540-x
- Ziel E, Hermann G, Sen N, et al. Survival benefit of surgery after chemoradiotherapy for stage III (N0-2) non-small-cell lung cancer is dependent on pathologic nodal response. J Thorac Oncol 2015;10:1475-80. https://doi.org/10.1097/JTO.0000000000000639
- Sonett JR, Krasna MJ, Suntharalingam M, et al. Safe pulmonary resection after chemotherapy and high-dose thoracic radiation. Ann Thorac Surg 1999;68:316-20. https://doi.org/10.1016/S0003-4975(99)00593-7
- Cerfolio RJ, Bryant AS, Jones VL, Cerfolio RM. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg 2009;35:718-23. https://doi.org/10.1016/j.ejcts.2008.12.029
- Cerfolio RJ, Bryant AS, Spencer SA, Bartolucci AA. Pulmonary resection after high-dose and low-dose chest irradiation. Ann Thorac Surg 2005;80:1224-30. https://doi.org/10.1016/j.athoracsur.2005.02.091
- Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86. https://doi.org/10.1016/S0140-6736(09)60737-6
- Ahn S, Na K, Kim Y, et al. Surgical Salvation after full-dose concurrent chemoradiation in patients with locally advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2014;90(1 Suppl):S619.
- Suntharalingam M, Paulus R, Edelman MJ, et al. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 2012;84:456-63. https://doi.org/10.1016/j.ijrobp.2011.11.069
- Senan S, Brade A, Wang LH, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-smallcell lung cancer. J Clin Oncol 2016;34:953-62. https://doi.org/10.1200/JCO.2015.64.8824
- Tam K, Daly M, Kelly K. Treatment of locally advanced non-small cell lung cancer. Hematol Oncol Clin North Am 2017;31:45-57. https://doi.org/10.1016/j.hoc.2016.08.009
- Blumenschein GR Jr, Paulus R, Curran WJ, et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011;29:2312-8. https://doi.org/10.1200/JCO.2010.31.7875
- Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-6. https://doi.org/10.1200/JCO.2007.14.4824
- Wozniak AJ, Moon J, Thomas CR Jr, et al. A pilot trial of cisplatin/etoposide/radiotherapy followed by consolidation docetaxel and the combination of bevacizumab (NSC-704865) in patients with inoperable locally advanced stage III nonsmall-cell lung cancer: SWOG S0533. Clin Lung Cancer 2015;16:340-7. https://doi.org/10.1016/j.cllc.2014.12.014
- Saxena A, Becker D, Preeshagul I, Lee K, Katz E, Levy B. Therapeutic effects of repurposed therapies in non-small cell lung cancer: what is old is new again. Oncologist 2015;20:934-45. https://doi.org/10.1634/theoncologist.2015-0064
- Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III nonsmall-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68. https://doi.org/10.1016/S1470-2045(13)70510-2
- Demaria S, Formenti SC. Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol 2007;83:819-25. https://doi.org/10.1080/09553000701481816
- Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15:5379-88. https://doi.org/10.1158/1078-0432.CCR-09-0265
- Seyedin SN, Schoenhals JE, Lee DA, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 2015;7:967-80. https://doi.org/10.2217/imt.15.65
Cited by
- Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy vol.12, pp.None, 2017, https://doi.org/10.1186/s13014-017-0848-2
- Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study† vol.53, pp.6, 2017, https://doi.org/10.1093/ejcts/ezx464
- Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary c vol.55, pp.2, 2017, https://doi.org/10.4103/ijc.ijc_469_17
- Clinical outcomes of carbon‐ion radiotherapy for locally advanced non‐small‐cell lung cancer vol.110, pp.2, 2017, https://doi.org/10.1111/cas.13890
- Less of a good thing - the paradox of reduced multidisciplinary team decision-making : Comment on Behrendt et al., p. 262-269 vol.48, pp.3, 2019, https://doi.org/10.1024/0301-1526/a000782
- High-Dose Thoracic Re-irradiation of Lung Cancer Using Highly Conformal Radiotherapy Is Effective with Acceptable Toxicity vol.51, pp.3, 2017, https://doi.org/10.4143/crt.2018.472
- Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy vol.12, pp.None, 2020, https://doi.org/10.2147/cmar.s248034
- Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer vol.15, pp.3, 2017, https://doi.org/10.1371/journal.pone.0230444